In and exclusion criteria


Inclusion criteria:

  • Diagnosis of primary esophageal adenocarcinoma or squamous cell carcinoma (cT1b-4a, N0-3, M0)
    • in the mid or distal esophagus or at the level of the gastroesophageal junction
    • scheduled for undergoing transthoracic esophagectomy with curative intent or for esophageal reconstruction with a gastric or jejunal interposition.
  • Age ≥ 18 years,
  • Able to give written informed consent

Exclusion criteria:

  • Patients planned for rescue surgery,
  • Patients planned for colonic interposition,
  • Known or suspected pregnancy,
  • Patients who have undergone upper GI surgery within 30 days before randomization,
  • Unable to understand the study information, study instructions and give informed consent.
  • Patients enrolled in a trial that would interact with the intervention,
  • Patients with a known allergy, sensitivity, or interaction to components of the investigational medicinal product,
  • Patients with known/documented colonization of Enterobacteriaceae and or Pseudomonas Aeruginosa that are resistant to both tobramycin/gentamicin and to carbapenem antibiotics,
  • Patients undergoing CVVH,
  • Patients with documented chronic renal failure (GFR < 15 mls/min) or who are on chronic intermittent hemo- or peritoneal dialysis,
  • Women of childbearing potential at risk of pregnancy, not using adequate contraception,
  • Patients with the inability to swallow the SDD,
  • Patients with pre-existing degenerative neuromuscular diseases like, but not limited to, myasthenia gravis or Parkinson disease).